This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04947/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04947/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04947/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04947/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04947
rdf:type
n3:Drug
n3:description
Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and attention deficit hyperactivity disorder (ADHD).
n3:generalReferences
# Cattabeni F: Altropane (Boston Life Science). Curr Opin Investig Drugs. 2002 Nov;3(11):1647-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12476968 # Fernandez HH, Friedman JH, Fischman AJ, Noto RB, Lannon MC: Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease? Med Sci Monit. 2001 Nov-Dec;7(6):1339-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11687754 # Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY, Stopa EG, Babich J, Fischman AJ: Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse. 1998 Jun;29(2):116-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9593102 # Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK: [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse. 2001 Mar 15;39(4):332-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11169784 # Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, Fischman AJ: Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse. 1998 Jun;29(2):93-104. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9593100 # Madras BK, Gracz LM, Meltzer PC, Liang AY, Elmaleh DR, Kaufman MJ, Fischman AJ: Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain. Synapse. 1998 Jun;29(2):105-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9593101 # Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR, Callahan RJ, Barrow SA, Graham W, Meltzer PC, Hanson RN, Madras BK: Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9593103
n3:group
investigational
n3:indication
Investigated for use/treatment in attention deficit/hyperactivity disorder (ADHD), parkinson's disease, and pediatric indications.
owl:sameAs
n6:DB04947
dcterms:title
Altropane
adms:identifier
n8:4944487 n10:11968480 n11:DB04947 n12:6440180
n3:mechanismOfAction
Positron emission tomography (PET) cameras are expensive and scarce, and the tests are non-reimbursable. A less costly and more available test such as a single photon emission computed tomography (SPECT) may be helpful in the diagnosis of early or atypical Parkinson's disease (PD) if its sensitivity is comparable to a PET scan. Altropane is an iodinated form of the N-allyl analog of WIN 35,428 which acts as a dopamine transport inhibitor. When radiolabeled with the gamma emitting isotope [123I], altropane serves as a SPECT ligand with high affinity and selectivity for the dopamine transporter. It is a good marker for dopamine neurons and is useful in detecting PD.
n3:IUPAC-Name
n4:271B608C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6092-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6091-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B608E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B608F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6090-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B608A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B608B-363D-11E5-9242-09173F13E4C5 n4:271B6088-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6089-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6098-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6099-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6093-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6094-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6096-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6095-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6097-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
180468-34-2
n3:category
n3:Bioavailability
n4:271B609D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B609F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B60A0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B609C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B609B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B609E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B608D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B609A-363D-11E5-9242-09173F13E4C5